psoriasis100.RdA dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing biologics at different doses and placebo (Warren et al. 2019) . The outcome is the number of patients experiencing 100% improvement on the Psoriasis Area and Severity Index (PASI) measured at 12 weeks follow-up. The dataset includes 19 Randomised-Controlled Trials (RCTs), comparing 8 different biologics at different doses with placebo.
psoriasis100A data frame in long format (one row per arm and study), with 81 rows and 9 variables:
studyID Study identifiers
agent Character data indicating the agent to which participants were randomised
dose_mg Numeric data indicating the dose to which participants were randomised in mg
freq Character data indicating the frequency of the dose to which participants were randomised
dose Numeric data indicating the dose in mg/week to which the participants were randomised
n Numeric data indicating the number of participants randomised
r Numeric data indicating the number of participants who achieved 100% improvement in PASI score after 12 weeks
Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A (2019). “Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.” J Am Acad Dermatol, 82(5), 1138-1149.